VCTE衍生CAP评分估计的肝脂肪变性与慢性肝病患者肝脏相关事件及全因死亡率降低相关
这项回顾性队列研究纳入7587例接受VCTE检查的美国退伍军人,随访至2022年1月1日。中位随访约1.9年,肝脂肪变(1-3级 vs 0级)与死亡风险降低相关(aHR 0.70,95%CI 0.57-0.85);在MASLD患者中,肝脂肪变与失代偿风险降低(aHR 0.54,95%CI 0.32-0.90)和死亡风险降低(aHR 0.52,95%CI 0.37-0.73)相关。
要点
- 肝脂肪变(1-3级 vs 0级)与全因死亡风险降低相关(aHR 0.70,95%CI 0.57-0.85)。
- MASLD患者中,肝脂肪变与失代偿风险降低相关(aHR 0.54,95%CI 0.32-0.90)。
- MASLD患者中,肝脂肪变与死亡风险降低相关(aHR 0.52,95%CI 0.37-0.73)。
核心结论
- 在接受VCTE检查的患者中,CAP评分估计的明显肝脂肪变与全因死亡率降低相关,在MASLD患者中与失代偿和死亡风险降低相关。
研究设计与样本
- 回顾性队列研究,纳入7587例美国退伍军人,其中丙型肝炎治愈2689例、酒精相关性肝病1523例、代谢功能障碍相关脂肪性肝病(MASLD)3375例。
- 患者于2015年5月至2021年12月期间接受VCTE检查,随访至2022年1月1日,中位随访时间约1.9年。
- 采用多变量Cox比例风险回归分析CAP测量值与临床结局的关联,并分别按疾病病因和晚期纤维化状态报告。
主要发现
- 肝脂肪变(1-3级 vs 0级)与死亡风险降低相关(aHR 0.70,95%CI 0.57-0.85)。
- MASLD患者中,肝脂肪变与失代偿风险降低相关(aHR 0.54,95%CI 0.32-0.90)。
- MASLD患者中,肝脂肪变与死亡风险降低相关(aHR 0.52,95%CI 0.37-0.73)。
- 在晚期纤维化及无肝硬化患者的亚组分析中,上述关联持续存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The controlled attenuated parameter (CAP) score derived from vibration-controlled transient elastography (VCTE, i.e., FibroScan) is a well-validated marker of hepatic steatosis. It is unclear whether CAP scores are associated with risks of liver-related outcomes or all-cause mortality. METHODS: In this retrospective cohort study, we identified 7,587 United States veterans (2,689 with cured hepatitis C [hepatitis C virus], 1,523 with alcohol-associated liver disease, and 3,375 with metabolic dysfunction-associated steatotic liver disease [MASLD]) who underwent VCTE between May 2015 and December 2021. We followed patients for new hepatic decompensation, hepatocellular carcinoma, and death from the VCTE date until January 1, 2022. Multivariable Cox-proportional hazards regression was used to assess for the associations between CAP measurements and clinical outcomes, adjusting for age, sex, race/ethnicity, body mass index, Charlson Comorbidity Index, diabetes, liver disease etiology, liver stiffness measurements, and Fibrosis-4 score, and was reported separately by disease etiology and advanced fibrosis status. RESULTS: Over a median follow-up time of ∼1.9 years, hepatic steatosis (grades 1-3 vs 0) was associated with a lower risk of death (adjusted hazard ratio [aHR] 0.70, 95% CI: 0.57-0.85). Among patients with MASLD, hepatic steatosis was associated with a lower risk of decompensation (aHR 0.54, 95% CI: 0.32-0.90) and death (aHR 0.52, 95% CI: 0.37-0.73). These associations persisted in subgroup analyses of patients with advanced fibrosis and without cirrhosis. DISCUSSION: Among patients who underwent VCTE in clinical practice, the presence of substantial hepatic steatosis estimated by the CAP score was associated with lower all-cause mortality among all patients and lower risk of decompensation and death among those with MASLD.
引用
- Kim NJ, Vutien P, Borgerding JA, et al. Hepatic Steatosis Estimated by VCTE-Derived CAP Scores Was Associated With Lower Risks of Liver-Related Events and All-Cause Mortality in Patients With Chronic Liver Diseases. Am J Gastroenterol. 2024. PMID: 39450884. doi:10.14309/ajg.0000000000003161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。